470 results on '"Kitko, Carrie L."'
Search Results
2. Comparison of treatment response measures in cutaneous sclerosis after allogeneic hematopoietic cell transplantation
3. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
4. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
5. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
6. Immunophenotypic predictors of influenza vaccine immunogenicity in pediatric hematopoietic cell transplant recipients
7. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
8. A Day 14 Endpoint for Acute GVHD Clinical Trials
9. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease
10. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
11. A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE/PBMTC 1202 study
12. Effective treatment of low-risk acute GVHD with itacitinib monotherapy
13. Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients
14. KIR-favorable TCR-αβ/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial
15. SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies
16. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis
17. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
18. Metabolomic identification of α-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease
19. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis
20. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
21. Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival
22. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium
23. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report
24. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report
25. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy
26. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report
27. Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report
28. Impact of the COVID‐19 Pandemic Onset on the Early Careers of Pediatric Oncology Health Professionals and Researchers: A Report From the Children's Oncology Group Young Investigators Committee, Young SIOP Network, and Young SIOPE.
29. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin
30. Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies
31. Flares of Acute Graft-Versus-Host Disease (GVHD): A Mount Sinai Acute GVHD International Consortium (MAGIC) Analysis
32. Safety and Efficacy of Axatilimab in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)
33. Ibrutinib for Therapy of Steroid-Refractory Chronic Graft Vs. Host Disease: A Multicenter Real-World Analysis
34. The Mount Sinai Acute Gvhd International Consortium (MAGIC) Model: An Integrated Clinical and Biomarker Grading System for Acute Graft-Versus-Host Disease (GVHD)
35. Assessing Treatment Response in Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation: A Chronic Gvhd Consortium Study
36. Graft Vs Host Disease (GVHD) in Pediatric Hematopoietic Stem Cell Transplant (HCT) Recipients and Impact on Overall Survival: A CIBMTR Analysis
37. The MAGIC Algorithm Probability Predicts Treatment Response and Long-Term Outcomes to Second-Line Therapy for Acute Gvhd
38. Effect of Autograft CD34+ Dose on Outcome in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors
39. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant
40. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research
41. Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia
42. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
43. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria
44. The role of biomarkers in risk stratification, treatment and outcome in acute GVHD
45. A comprehensive assessment of the prolonged febrile neutropenia evaluation in pediatric oncology patients
46. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
47. Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers
48. The utility of biomarkers in acute GVHD prognostication
49. Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantation
50. Pilot Study of Donor-Engrafted Clonal Hematopoiesis Evolution and Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation Recipients Using a National Registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.